Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334158 | 0.94 | RARB (0.56) | TDP1DRD4DRD2DRD3RARB | |
| SCHEMBL941201 | 0.90 | TDP1 (0.66) | TDP1DRD4DRD2DRD3KDM4E | |
| SCHEMBL6852447 | 0.88 | TDP1 (0.50) | TDP1DRD4DRD2DRD3RARB | |
| SCHEMBL4826829 | 0.84 | RARB (0.50) | TDP1DRD4DRD2DRD3RARB | |
| SCHEMBL9145315 | 0.83 | KDM4E (0.50) | TDP1DRD4DRD2DRD3KDM4E | |
| SCHEMBL9146738 | 0.83 | KDM4E (0.50) | TDP1DRD4DRD2DRD3KDM4E | |
| SCHEMBL24482993 | 0.82 | NQO1 (0.58) | TDP1RARBKDM4EALDH1A1MAPK1 | |
| SCHEMBL13251251 | 0.82 | MEN1 (0.57) | TDP1DRD4DRD2DRD3RARB | |
| SCHEMBL13251236 | 0.82 | TDP1 (0.55) | TDP1DRD4DRD2DRD3RARB | |
| SCHEMBL17445905 | 0.80 | ATM (0.60) | TDP1DRD4DRD2DRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | TDP1 1486/4885DRD4 3616/4885DRD2 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.